In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line

BACKGROUND: Colorectal cancer is common to both sexes; third in terms of morbidity and second in terms of mortality, accounting for 10% and 9.2% of cancer cases in men and women globally. Although drugs such as bevacizumab, Camptosar, and cetuximab are being used to manage colorectal cancer, the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikwu, Fabian Adakole, Isyaku, Yusuf, Obadawo, Babatunde Samuel, Lawal, Hadiza Abdulrahman, Ajibowu, Samuel Akolade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492310/
https://www.ncbi.nlm.nih.gov/pubmed/32930901
http://dx.doi.org/10.1186/s43141-020-00066-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492310/
https://www.ncbi.nlm.nih.gov/pubmed/32930901
http://dx.doi.org/10.1186/s43141-020-00066-2

Ejemplares similares